Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium
Wednesday, September 12, 2018, 8:00 AM - 2:30 PM
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
The New York Academy of Sciences
Cancer immunotherapies utilize the body’s own immune defenses to kill tumor cells. James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center has dedicated his career to better understanding the immune system and leveraging it to treat cancer. Dr. Allison led the development of ipilimumab, a cancer immunotherapy that targets CTLA-4, a receptor that effectively turns “off” immune cells. By inhibiting CTLA-4, ipilimumab activates the immune response to target and kill cancer cells. Ipilimumab was the first immune checkpoint inhibitor approved by the U.S. Food and Drug Administration, achieving long-standing remission of metastatic melanoma in some cases. Its success has helped to establish immunotherapy as a viable and effective strategy more broadly. For his extensive characterization of immune regulation and development of therapies that have dramatically improved the treatment of certain cancers, Dr. Allison will receive the 2018 Dr. Paul Janssen Award for Biomedical Research.
Similar to ipilimumab, other immune checkpoint inhibitors that activate the immune response to cancer through different molecular targets also have recently been deployed to treat a number of different cancers. Beyond immune checkpoint blockade, the field of immune-oncology has grown to include several therapeutic strategies, currently in various stages of development — including cytokine therapy, cancer vaccines, and harvesting and modifying patients’ immune cells (as in CAR-T treatments). Further studies of the immune response to cancer, and of the dynamics of the broader tumor microenvironment, will aid the development and optimization of these therapies. Work is ongoing to apply immunotherapies to new cancers and patients, to understand how best to use them in combination, and to reduce the risk of potentially dangerous side effects.
This half-day symposium, Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium, will celebrate the work of Dr. Allison, who will review recent advances. Following his award lecture, fellow prominent scientists will discuss several aspects of cancer immunotherapy, from the basic understanding of immune regulation to the development of therapies in the clinic.
September 12, 2018
Registration and Breakfast
Welcome and Introductory Remarks
SESSION I: The Past and the Future of Cancer Immunotherapy
2018 Dr. Paul Janssen Award for Biomedical Research Announcement
2018 Dr. Paul Janssen Award for Biomedical Research Lecture
SESSION II: Emerging Approaches in Cancer Immunotherapy
Coffee and Networking Break
Oncolytic Viruses: Past Present Future